REFERENCES
- Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252: 283–294.
- Ridker PM, Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10:S9–S12.
- Rifai N. C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol 2001;1:153–157.
- Benzaquen LR, Yu H, Rifai N. High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002; 39: 459–497.
- Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol 2003;92(4B):17K–22K
- Wong TY, Mitchell P. The eye in hypertension. N Engl J Med 2007;369:425–435.
- Porta M, Grosso A Veglio F. Hypertensive retinopathy: there's more than meets the eye. J Hypertens 2005;23:683–696.
- Wong TY, McIntosh R. Hypertensive retinopathy signs as risk indicators of cardiovascular morbidity and mortality. Br Med Bull 2005;73–74:57–70.
- Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974;268:336–345.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560–2572.
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). JAMA 2001; 285:2486–2497.
- Friedewald WT, Levi RI, Fredricksen DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
- Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, Park JR, Kim SW. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003;16:429–433.
- Bautista LE, Lopez-Joramillo P, Vera LM, Is C-reactive protein an independent risk factor for essential hypertension?? J Hypertens 2001;19:857–861.
- Ozdogan M, Bozcuk H, Coban E. Low grade inflammation in white-coat hypertension. Med Sci Monit 2007;13: CR570–CR573.
- Yilmaz MI, Sonmez A, Kilic S, The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol 2005;152:233–40.
- Svardsudd K, Wedel H, Aurell E, Tibblin G. Hypertensive eye ground changes. Prevalence, relation to blood pressure and prognostic importance. The study of men born in 1913. Acta Med Scand 1978;204:159–167.
- Lowenthal MN, Zimlichman R. Resolution of hypertensive retinopathy despite persistent high diastolic pressure. South Med J 1993;86:190–193.
- Hubbard LD, Brothers JR, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, Davis MD, Cai J. Methods for evaluation of retinal microvascular abnormalities associated with hypertension//sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269–2280.
- Takiuchi S, Kamide K, Miwa Y, Tomiyama M, Yoshii M, Matayoshi T, Horio T, Kawano Y. Diagnostic value of carotid intima-media thickness and plaque score for predicting target organ damage in patients with essential hypertension. J Hum Hypertens 2004;18:17–23.
- Ebinc H, Ebinc FA, Ozkurt ZN. Relationship of early hypertensive retinopathy to inflammation markers and microalbuminuria in hypertensive patients with regulated blood pressure. Saudi Med J 2007; 28:472–473.